July 15, 2026
AdvanCell
AdvanCell is a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer.
- Round
- Series D
- Amount raised
- $315M
- Lead investor
- Ally Bridge Group
- Industry
- Biotechnology
- Headquarters
- Australia
- Employees
- 51-200 employees
- Website
- advancell.com.au
- View profile →
Source: FinSMEs